辉瑞VS诺和诺德:千亿美金的王座与赌局

建国路128号
Nov 06, 2025

2025年的Q4,宇宙大药厂辉瑞,和刚刚体验完“药王一日游”的诺和诺德杠上了。焦点是一家名为Metsera的公司,这是一家拿着“每月注射一次”的GLP-1和新一代Amylin的潜力管线的公司——被两位重量级的买家争来争去。天平的一端,“减肥药之王”诺和诺德试图用一份“合规且更优”的报价,来续写司美的神话;而在另一边,辉瑞在错过了免疫、双抗、ADC等近年主流领域之后,不断借助新冠期间攒下的“千亿家底...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10